- Home
- KRP vs PCRX Comparison
KRP vs PCRX Comparison
Compare KRP & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRP
- PCRX
- Stock Information
- Founded
- KRP 2013
- PCRX 2006
- Country
- KRP United States
- PCRX United States
- Employees
- KRP N/A
- PCRX N/A
- Industry
- KRP Oil & Gas Production
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- KRP Energy
- PCRX Health Care
- Exchange
- KRP Nasdaq
- PCRX Nasdaq
- Market Cap
- KRP 1.2B
- PCRX 1.2B
- IPO Year
- KRP 2017
- PCRX 2011
- Fundamental
- Price
- KRP $13.26
- PCRX $21.27
- Analyst Decision
- KRP Hold
- PCRX Buy
- Analyst Count
- KRP 5
- PCRX 5
- Target Price
- KRP $17.20
- PCRX $32.40
- AVG Volume (30 Days)
- KRP 366.4K
- PCRX 510.9K
- Earning Date
- KRP 11-06-2025
- PCRX 11-06-2025
- Dividend Yield
- KRP 12.97%
- PCRX N/A
- EPS Growth
- KRP N/A
- PCRX N/A
- EPS
- KRP N/A
- PCRX N/A
- Revenue
- KRP $312,566,668.00
- PCRX $705,848,000.00
- Revenue This Year
- KRP $8.37
- PCRX $7.27
- Revenue Next Year
- KRP $0.38
- PCRX $10.18
- P/E Ratio
- KRP N/A
- PCRX N/A
- Revenue Growth
- KRP N/A
- PCRX 2.25
- 52 Week Low
- KRP $10.98
- PCRX $16.00
- 52 Week High
- KRP $16.99
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- KRP 47.80
- PCRX 33.18
- Support Level
- KRP $13.20
- PCRX $20.50
- Resistance Level
- KRP $13.46
- PCRX $21.90
- Average True Range (ATR)
- KRP 0.22
- PCRX 0.85
- MACD
- KRP 0.05
- PCRX -0.07
- Stochastic Oscillator
- KRP 70.13
- PCRX 38.55
About KRP Kimbell Royalty Partners Common Units Representing Limited Partner Interests
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.